Canadian Cancer Trials Group Bulletins

Trial Management Group


Trial Activations

Two trials were recently activated -- Canadian Cancer Trials Group PA.6 (PRODIGE/ACCORD24) was centrally activated on July 18, 2012 and Canadian Cancer Trials Group SR.6 (SARC021) was activated today, July 20, 2012.

Canadian Cancer Trials Group PA.6 (PRODIGE/ACCORD24) -- A Multi-Centre, Randomized Phase III Study Comparing 6-Month Adjuvant Chemotherapy with Gemcitabine vs 5-Fluorouracil, Leucovorin, Irinotecan and Oxaliplatin (mFOLFIRINOX) in Patients with Resected Pancreative Adenocarcinoma -- was centrally activated on July 18, 2012.

For Canadian centres only -- in order to permit us to expedite essential processes with the lead group, please confirm your interest in participating in this trial to Ms. Barbara Graham, Canadian Cancer Trials Group Study Coordinator as soon as possible at 613-533-6430 or bgraham@ctg.queensu.ca.

________________________

Canadian Cancer Trials Group SR.6 (SARC021) -- A Randomized Phase III, Multicentre, Open-Label Study Comparing TH-302 in Combination with Doxorubicin vs. Doxorubicin Alone in Subjects with Locally Advanced Unresectable or Metastatic Soft Tissue Sarcoma -- was centrally activated on July 20, 2012.

For more information about this trial, please contact Ms. Cathy Davidson, Canadian Cancer Trials Group Study Coordinator, at 613-533-6430 or cdavidson@ctg.queensu.ca.